Immunosuppression Post-Liver Transplant
Clinics in Liver Disease · 2025
DOI: 10.1016/j.cld.2024.12.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Liver Disease, 2025. Verfasst von Maria L Yataco und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Calcineurin Inhibitors, Immunosuppressive Agents, Graft Rejection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
The introduction of calcineurin inhibitors (CNIs) as the primary form of immunosuppression (IS) for liver transplantation (LT) in the late 1970s was a key in increasingly successful outcomes for transplantation over the past 3 decades. Despite the side effects of CNI which directly contribute to the long-term morbidity and mortality post-LT, they will remain the cornerstone of IS in the near future. Efforts to minimize exposure to CNI will require the application of blood and tissue biomarkers that accurately identify the extent of IS and risk of rejection for individual patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
- Department of Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: Keaveny.andrew@mayo.edu.
Zitieren
APA
Yataco, M. L., & Keaveny, A. P. (2025). Immunosuppression Post-Liver Transplant. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2024.12.006
Vancouver
Yataco ML, Keaveny AP. Immunosuppression Post-Liver Transplant. Clinics in Liver Disease. 2025. doi:10.1016/j.cld.2024.12.006
BibTeX
@article{Yataco2025,
author = {Yataco, Maria L and Keaveny, Andrew P},
title = {Immunosuppression Post-Liver Transplant},
journal = {Clinics in Liver Disease},
year = {2025},
doi = {10.1016/j.cld.2024.12.006}
}
EUVIMED